Introduction {#Sec1}
============

Nitric oxide (NO) injury can lead to various neurological diseases, such as Alzheimer's disease \[[@CR1]\] and Parkinson's disease \[[@CR2], [@CR3]\]. Sodium nitroprusside (SNP) is a donor of NO \[[@CR4]\] and is widely used to induce NO damage in models. Currently, SNP injury mechanisms include mitochondrial damage \[[@CR5]\], calcium overload \[[@CR6]\], and the promotion of apoptosis and more specifically involve the glycogen synthase kinase 3/mitogen-activated protein kinase signaling pathway \[[@CR7]\] and reactive oxygen \[[@CR8]\]. However, the role of neurotransmitters of the adrenergic system in the regulation of the nervous system in vivo is unknown, and the effect of the adrenergic system in the protection against SNP injury is not clear.

The adrenergic system plays an important role in neurological diseases, especially for mental illness, such as depression, and cerebral ischemia. The depressant effects of certain antipsychotic drugs appear to be mediated by the central adrenergic system \[[@CR9], [@CR10]\]. One predominant biological response to acute stress is the release of norepinephrine, which activates the peripheral stress response and the hypothalamic--pituitary--adrenal (HPA) axis \[[@CR11]\]. Partial β1-adrenergic receptor agonists can be used for the treatment of neurocognitive disorders \[[@CR12]\], and β2-adrenergic receptor antagonists attenuate the brain damage induced by ischemia \[[@CR13], [@CR14]\].

Rat pheochromocytoma PC12 cells are typically used as models \[[@CR15]\] for studying neuronal degeneration disorders such as Alzheimer's disease \[[@CR16]\] and Parkinson's disease. They are also intensively used to investigate the reactive oxygen species (ROS) and NO synthase (NOS) \[[@CR17]\] biochemical pathways involved in cell death and neuroprotection. Neuroblastoma SH-SY5Y cells, a cell line derived from human neuroblastomas, are also widely used in the study of the nervous system due to their cell growth and differentiation ability. Therefore, SNP-induced neurotoxicity in PC12 and SH-SY5Y cells are suitable to evaluate neuroprotective candidates. However, PC12 cells cannot produce adrenaline (AD), while SH-SY5Y cells can produce tyrosine hydroxylase, dopamine 2B2 hydroxylase, and dopamine transporters, which are characteristic of catecholaminergic neurons.

In view of the lack of research on whether the adrenergic system is involved in NO damage, we explored the effects of different adrenergic receptor agonists and antagonists in gradient doses on cell viability. We also researched the role of the α-adrenergic receptors and β-adrenergic receptors in the neuroprotective effect of ganoderic acid A on SNP injury.

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

Ganoderic acid A (purity \> 90%) was isolated in the Department of Natural Medicinal Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences, and the structure is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1**The structure of ganoderic acid A.**

Metoprolol was purchased from Shanghai Dingkang Biomedical Materials Technology Co., Ltd. (China). *[dl]{.smallcaps}*-Adrenalin was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (China). Phentolamine hydrochloride, ICI 118551, SNP, and 3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM) and horse serum (HS) were obtained from Gibco Life Technologies Inc. (Grand Island, NY, USA). Fetal bovine serum (FBS) was purchased from PAN Seratech Co. (Aidenbach, Germany).

Cell culture and treatment {#Sec4}
--------------------------

Both the SH-SY5Y and PC12 cell lines were obtained from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. SH-SY5Y cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a 5% CO~2~ atmosphere incubator, and PC12 cells were cultured in DMEM supplemented with 5% FBS, 5% HS, 100 U/mL penicillin, and 100 μg/mL streptomycin. The medium was refreshed every 2 or 3 days.

The cells were collected when they had grown to 80%--90% confluence and were then treated with different concentrations of SNP for 12, 24, and 48 h to determine the optimal damage condition. After the SNP damage model was established, the cells were treated with SNP (500 μM) for 24 h or were preincubated with ganoderic acid A at a 10 μM concentration for 2 h before SNP exposure. The control group received equal-volume medium without SNP, and the model group was not preincubated with drugs. Different adrenergic receptor agonists and antagonists were separately added into the 96-well plates 1 h before ganoderic acid A preincubation to research the mechanism. Medium without SNP was added to the control group cells, and the model group received no preincubation with drugs. To properly choose suitable concentrations of adrenergic receptor agonists and antagonists, cells were treated with phentolamine, ICI 118551, metoprolol, and AD at concentrations of 0.1, 1, 3, 10, 30, and 100 μM for various intervals. Then, the cell viability was determined by the MTT method.

Determination of cell viability {#Sec5}
-------------------------------

To determine the cell viability, an MTT assay (0.5 g/L) was conducted in a 96-well plate (5 × 10^3^ SH-SY5Y cells/wells and 8 × 10^3^ PC12 cells/wells) for 4 h at 37 °C and incubated with the cells after 24 h of exposure to SNP. The dark blue formazan crystals formed in intact cells were solubilized in dimethyl sulfoxide and detected at 570 nm using a microplate reader.$$\documentclass[12pt]{minimal}
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Assay of extracellular NO {#Sec6}
-------------------------

The NO content was measured following the kit instructions using the Griess reaction. Sulfanilamide was added to the supernatant, and the mixture was incubated for 5 min at room temperature. Then, *N*-1-naphthylethylenediamine dihydrochloride was added for another 5 min at room temperature, and the absorbance was measured at 540 nm.

Assay of cellular AD and NE {#Sec7}
---------------------------

The levels of AD and NE were measured by enzyme-linked immunosorbent assay. After treatment, the cells in the 96-well plates were broken by lysates and centrifuged. The AD and NE levels in the supernatant were determined according to the guidelines of the kit by analysis on a microplate reader, and the maximum absorption peak was at 450 nm. The AD and NE levels were calculated using a standard calibration curve and expressed in pg/mL.

Statistical analysis {#Sec8}
--------------------

All data were analyzed using the SPSS 22.0 software package and are expressed as the means ± standard deviation (SD). In vitro results were analyzed by a *t* test and one-way analysis of variance followed by Tukey's post hoc test. Probability (*P*) values \<0.05 were considered statistically significant.

Results {#Sec9}
=======

AD induced cytotoxicity and increased NO contents in both SH-SY5Y and PC12 cells {#Sec10}
--------------------------------------------------------------------------------

We chose different concentrations of AD at 0.1, 1, 3, 10, 30, and 100 μM to detect the cell viability and NO contents. As a result, 30 and 100 μM AD induced significant cytotoxicity in both SH-SY5Y and PC12 cells, and a high concentration of AD increased the NO content in the cell supernatant, which was similar to SNP injury (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2The effects of different concentrations of adrenaline on the viability and NO contents of cells in 24 h.Cells were exposed to various concentrations of adrenaline for 24 h. The viability was estimated by MTT assay and NO contents were detected using Griess reaction. **a**, **b** The effects of adrenaline on the viability of SH-SY5Y and PC12 cells; **c**, **d** The effects of adrenaline on the NO contents of SH-SY5Y and PC12 cells. Data were represented as the mean ± SD from three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 as compared with control cells.

Adrenergic receptor antagonists induced cytotoxicity in both SH-SY5Y and PC12 cells {#Sec11}
-----------------------------------------------------------------------------------

We chose different concentrations of phentolamine, metoprolol, and ICI 118551 at 0.1, 1, 3, 10, 30, and 100 μM to detect the cell viability of SH-SY5Y and PC12 cells. As a result, phentolamine, metoprolol, and ICI 118551 at high concentrations (especially 30 and 100 μM) all induced cytotoxicity significantly in both neural cell lines (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3The effects of different concentrations of adrenergic receptor antagonists on the viability of cells in 24 h.Cells were exposed to various concentrations of phentolamine, metoprolol, and ICI 118551 for 24 h. The viability was estimated by MTT assay and NO contents were detected using Griess reaction. **a**, **b** The effect of phentolamine on the viability of SH-SY5Y and PC12 cells; **c**, **d** effect of metoprolol on the viability of SH-SY5Ys and PC12 cells; **e**, **f** effect of ICI 118551 on the viability of SH-SY5Y and PC12 cells. Data were represented as the mean ± SD from three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 as compared with control cells.

Ganoderic acid A showed differences in cytotoxicity and NO contents between SH-SY5Y and PC12 cells {#Sec12}
--------------------------------------------------------------------------------------------------

As shown in Fig. [4a, b](#Fig4){ref-type="fig"}, the damage caused by SNP showed a time- and dose-effect relationship on both SH-SY5Y and PC12 cells. The effect of SNP on cell viability increased as time and concentration increased. The cell viability decreased rapidly with the increase in the concentration of SNP from 0 to 500 μM, and then the degree of damage tended to be mild. The damage caused by SNP at 24 h was much more serious than that caused at 12 h at the same concentration, and the difference in damage between 48 and 24 h was not very significant. Therefore, we chose 500 μM SNP for 24 h for our follow-up experiments, for which the cell viability was 53.61% ± 7.37% and 47.82% ± 0.86%, respectively, for SH-SY5Y and PC12 cells.Fig. 4The effects of ganoderic acid A on the viability and NO contents of SH-SY5Y and PC12 cells exposed to SNP.The viability was estimated by MTT assay and the NO contents were estimated using the supernatant of cell culture medium. **a**, **b** The inhibitory effects of SNP on SH-SY5Y and PC12 cells; **c** effects of GA A on the viability of SH-SY5Y and PC12 cells exposed to SNP; **d** effects of GA A on the NO contents of SH-SY5Y and PC12 cells exposed to SNP. Data were represented as the mean ± SD from three independent experiments. \*\**P* \< 0.01, \*\*\**P* \< 0.001 as compared with control cells in **a**, **b**. ^\#\#\#^*P* \< 0.001 as compared with control cells; \*\*\**P* \< 0.001 as compared with SNP-exposed cells in **c**, **d**.

Both cell lines were pretreated with ganoderic acid A (10 μM) for 2 h prior to the 24-h exposure to 500 μM SNP to assess the protective effect. The viability of the cells pretreated with ganoderic acid A was significantly increased compared with SH-SY5Y cells treated with SNP alone, but the protective effect of ganoderic acid A on PC12 cells was not significant (Fig. [4c](#Fig4){ref-type="fig"}). SNP was used to induce the generation of NO. As shown in Fig. [4d](#Fig4){ref-type="fig"}, both SH-SY5Y and PC12 cells showed a significant increase in the supernatant NO level when exposed to SNP compared with the control group cells, and this effect was significantly ameliorated by pretreating SH-SY5Y cells with 10 μM ganoderic acid A. However, the NO level was still high in PC12 cells.

Differences between SH-SY5Y and PC12 cells in the generation of AD and NE increased by ganoderic acid A {#Sec13}
-------------------------------------------------------------------------------------------------------

As shown in Fig. [5](#Fig5){ref-type="fig"}, the incubation of SH-SY5Y cells with SNP resulted in no significant difference in AD and NE content compared with the control group cells. Ganoderic acid A significantly increased the generation of AD and NE. Moreover, both the AD and the NE content of ganoderic acid A-treated cells were significantly different in the two cell lines. The AD content was significantly higher in the SH-SY5Y cells than in the PC12 cells, and the NE content was significantly higher in the PC12 cells than in the SH-SY5Y cells.Fig. 5The effects of ganoderic acid A on the AD and NE contents of SH-SY5Y and PC12 cells.Cells were exposed to SNP for 24 h with or without ganoderic acid A pretreatment at 10 μM concentrations for 2 h. The AD and NE level was estimated using the supernatant of cell culture medium. **a** The effects of GA A on the AD content of SH-SY5Y and PC12 cells; **b** effects of GA A on the NE content of SH-SY5Y and PC12 cells. Data were represented as the mean ± SD from three independent experiments. \*\*\**P* \< 0.001 as compared with control cells, ^\#\#^*P* \< 0.01 and ^\#\#\#^*P* \< 0.001 when compared between SH-SY5Y and PC12 cells.

Different agonists and antagonists of adrenergic receptors changed the protective effect of ganoderic acid A {#Sec14}
------------------------------------------------------------------------------------------------------------

One of the differences between SH-SY5Y and PC12 cells is that SH-SY5Y cells can synthesize epinephrine. AD is an agonist of the adrenal receptors, and we added AD to PC12 cells to retest the protective effect of ganoderic acid A on cell viability in SNP injury. As shown in Fig. [6a](#Fig6){ref-type="fig"}, AD (10 μM) itself had no effect on the cell viability of PC12 cells. Ganoderic acid A showed a protective effect against SNP injury in PC12 cells when combined with AD.Fig. 6Changes of different agonist and antagonists of adrenergic receptors on protective effect of ganoderic acid A.Cells were exposed to SNP for 24 h with or without GA A pretreatment at 10 μM concentrations for 2 h and cells were preincubated with different agonist or antagonists for 1 h before GA A added into the cell culture fluid. The viability was estimated by MTT assay. **a** The effect of GA A co-incubated with adrenaline on cell viability of PC12 cells; **b** effect of GA A co-incubated with phentolamine on cell viability of SH-SY5Y cells; **c** effect of GA A co-incubated with metoprolol on cell viability of SH-SY5Y cells; **d** effect of GA A co-incubated with ICI 118551 on cell viability of SH-SY5Y cells. Data were represented as the mean ± SD from three independent experiments. ^\#\#\#^*P* \< 0.001 as compared with control cells, \**P* \< 0.05, as compared with SNP-exposed cells.

Phentolamine is an antagonist of the α-adrenergic receptor. As shown in Fig. [6b](#Fig6){ref-type="fig"}, phentolamine (0.1 μM) itself had no effect on the viability of SH-SY5Y cells. There was no significant difference in the protective effect of ganoderic acid A, which enhanced cell viability regardless of whether it was used alone or in combination with phentolamine.

Metoprolol is an antagonist of the β1-adrenergic receptor, and ICI 118551 is an antagonist of the β2-adrenergic receptor. As shown in Fig. [6c, d](#Fig6){ref-type="fig"}, metoprolol (10 μM) and ICI 118551 (0.1 μM) had no effect on the viability of SH-SY5Y cells. However, metoprolol and ICI 118551 blocked the protective effect of ganoderic acid A on SNP injury in SH-SY5Y cells.

Discussion {#Sec15}
==========

The process of neural cell damage is often accompanied by an imbalance of the adrenergic system \[[@CR18], [@CR19]\]. Some drugs acting on adrenergic receptors, such as AD and isoproterenol, can induce myocardial injury \[[@CR20], [@CR21]\]. Reduced β-adrenergic receptor (β-AR) responsiveness could improve liver damage and myocardial injury \[[@CR22]\], and a β2-adrenergic receptor (β2-AR) agonist could aid in the recovery of ischemia--reperfusion injury \[[@CR23]\]. SNP is a donor of NO; therefore, we established an excessive NO damage model induced by SNP to study the role of the adrenergic system in nerve injury \[[@CR24]--[@CR27]\].

In our experiments, AD at low concentrations had little effect on the cell viability of both SH-SY5Y cells and PC12 cells, but AD at high concentrations significantly increased cell NO production and caused a significant reduction in cell viability, which was similar to the effect of SNP. Different adrenergic receptor antagonists all reduced cell viability at high concentrations. We found and confirmed that the excessive activation of the adrenergic system induced great damage to the nervous system, which made sense because many neurological diseases, such as Alzheimer's disease \[[@CR28], [@CR29]\] and depression \[[@CR30], [@CR31]\], involve changes in the adrenergic system. We give the most direct proof of the association between adrenergic receptors and SNP injury, which helps in the understanding of the role of the adrenergic system in neurological diseases.

The most important difference between SH-SY5Y and PC12 cells is that PC12 cells cannot produce AD, and ganoderic acid A showed significant protective effects on SH-SY5Y cells, but weak protective effects on PC12 cells. Furthermore, significant differences in AD and NE content between the two cell lines were detected. Therefore, we hypothesized that the adrenergic system participated in the protective effect of ganoderic acid A on SH-SY5Y cells against SNP injury. We further supported this hypothesis by supplementing with AD and antagonizing α- or β-adrenergic receptors. Antagonists of α-adrenergic receptors are often used in the treatment of hypertension and urinary retention, work in the peripheral vasculature and inhibit the uptake of catecholamines in smooth muscle cells, resulting in vasodilation and blood pressure lowering \[[@CR32]\]. Additionally, β-adrenergic receptors have often been researched in antihypertensive treatment \[[@CR33]\], energy metabolism regulation \[[@CR34]\], cardiovascular disease treatment \[[@CR35]\], and anticancer treatment \[[@CR36]\]. However, the adrenergic system has not drawn attention in the protection of the nervous system. What we found could effectively prove that the adrenergic system participated in the protection of neural cells against SNP injury, and this is also the highlight of our article.

It has been reported that β-adrenergic receptors are activated in long-term depression \[[@CR37], [@CR38]\], and antagonists can regulate depression \[[@CR39]\] and show important significance during cerebral ischemia \[[@CR40]\]; in addition, noradrenergic dysfunction has been found in Alzheimer's disease \[[@CR41]\]. Neurological diseases are always accompanied by nerve injury. The damage mechanisms involve oxidative stress \[[@CR42]\], mitochondrial damage \[[@CR43]\], hypoxia--ischemia \[[@CR44]\], neuroinflammation \[[@CR45], [@CR46]\], and other pathways. We believe that neurotransmitters of the adrenergic system also play an important role in the regulation of the nervous system but lack awareness. Our experiments proved that β-adrenergic receptors participated in the protective effect of ganoderic acid A on neural cells, whereas α-adrenergic receptors had little effect on this process, but whether the β-adrenergic receptors participate in the other mechanisms of nerve damage and the detailed effects of different subtypes of adrenergic receptors still require further research.

Conclusions {#Sec16}
===========

The excessive AD system had great damage to the nervous system, and β-adrenergic receptors played an important role in the protective effect of ganoderic acid A on SH-SY5Y cells against NO injury induced by SNP.

This project was supported by the CAMS Innovation Fund for Medical Sciences (2017-I2M-1-010, China), the Drug Innovation Major Project (2018ZX09711001-003-005, China), and the Peking Union Medical College Graduate Innovation Fund Project (2017-1007-11).

ZRY and GHD designed research; ZRY performed research; HGY and GRH contributed new analytical tools; CL, HQW, and RYC contributed ganoderic acid A with high purity; ZRY, WHJ analyzed data; ZRY wrote the paper. All authors reviewed the manuscript.

The authors declare no competing interests.
